The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β‐thalassemia major: A prospective, single center, open‐label study

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 9, 2015-09 ,pp. : 1592-1596

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 2, 2015-02 ,pp. : 91-96

John Wiley & Sons Inc

Access to resources Recommend Favorite

Costs, quality of life, treatment satisfaction and compliance in patients with β-thalassemia major undergoing iron chelation therapy: the ITHACA study

By Scalone Luciana   Mantovani Lorenzo G.   Krol Marieke   Rofail Diana   Ravera Simona   Grazia Bisconte Maria   Borgna-Pignatti Caterina   Borsellino Zelia   Cianciulli Paolo   Gallisai Domenico   Prossomariti Luciano   Stefàno Ippazio   Cappellini Maria D.  

Current Medical Research and Opinion, Vol. 24, Iss. 7, 2008-07 ,pp. : 1905-1917

Informa Healthcare

Access to resources Recommend Favorite

Deferasirox Decreases Liver Iron Concentration in Iron-Overloaded Patients with Myelodysplastic Syndromes, Aplastic Anemia and Other Rare Anemias

By  

Acta Haematologica, Vol. 134, Iss. 4, 2015-0 ,pp. : 233-242

Karger

Access to resources Recommend Favorite

Clinical relevance of deferasirox trough levels in β‐thalassemia patients

By  

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (ELECTRONIC), Vol. 45, Iss. 2, 2018-02 ,pp. : 213-216

John Wiley & Sons Inc

Access to resources Recommend Favorite